Burden of cardiovascular disease in Japanese cancer patients and survivors: a single cancer-center study in Niigata City

Abstract

One in 10 elderly cancer survivors has serious CVD. AF, VTE, and heart failure were critical comorbidities. Cardiologists and cancer-care providers should recognize CVD presence and monitor patients closely, providing medications or interventions concurrently with cancer therapy.

Future projection of cancer patients with cardiovascular disease in Japan by the year 2039: a pilot study

“…CVD is endemic among cancer patients; hypertension, atrial fibrillation (AF), ischemic heart disease (IHD), venous thromboembolism (VTE), LVD, and heart failure (HF) are common comorbidities [5, 6]. This is attributable to common risk factors shared by cancer and CVD (e.g., aging, smoking, diabetes, obesity, and physical inactivity), neoplastic effects on the cardiovascular system, chemotherapy- and radiotherapy-induced cardiovascular toxicities, and longer life expectancies [1, 3, 6–9].…”

“…Curative surgery may be abandoned in favor of palliative surgery or radiotherapy. In our registry, the 5-year survival rate was 64.0% for all cancer patients and 44.2% for cancer patients with CVD [6]. Comorbidities with AF, VTE, and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) elevation were significantly associated with mortality [6].…”

The Impending Epidemic of Cardiovascular Diseases in Patients With Cancer in Japan

“…Hypertension, atrial fibrillation (AF), ischemic heart disease (IHD), venous thromboembolism (VTE), left ventricular dysfunction (LVD), and heart failure (HF) are common comorbidities in patients with cancer. [10][11][12] Navi et al 13 reported that patients with newly diagnosed cancer faced a considerably increased short-term risk of arterial thromboembolism. Within 6 months of diagnosis, more than twice as many patients with cancer had experienced arterial thromboembolism as matched controls without cancer.…”

“…83 However, cancer VTE imposes a huge burden on patients with cancer because it is a poor prognostic factor (Figures 2,3A) and causes post-thrombotic syndrome. 11,[80][81][82][83] Pulmonary thromboembolism (PTE) is the most common cause of postoperative death in cancer. In high-risk patients undergoing major surgery, pharmacological VTE prophylaxis is recommended with an acceptable bleeding risk and mechanical prophylaxis is recommended when the bleeding risk is unacceptable.…”

“…We used the statistics derived from the Niigata Cancer Center CVD Study (2015), as well as the population estimates from the National Cancer Center's Cancer Registry and Statistics survey of 2017 for future projections of onco-cardiology (Figure 4). 11,16,69 The total number of Japanese cancer patients with CVD was 253,000 in 2015 and is predicted to rapidly increase by 30,000 by 2020 and demonstrate a peak of 313,000 during 2030-2034. 69 The CVD population will predominately include men, with a 2.5-fold higher number than women.…”